IL173002A - Use of calcitonin in the manufacture of oral medication for the prevention or treatment of osteoarthritis - Google Patents
Use of calcitonin in the manufacture of oral medication for the prevention or treatment of osteoarthritisInfo
- Publication number
- IL173002A IL173002A IL173002A IL17300206A IL173002A IL 173002 A IL173002 A IL 173002A IL 173002 A IL173002 A IL 173002A IL 17300206 A IL17300206 A IL 17300206A IL 173002 A IL173002 A IL 173002A
- Authority
- IL
- Israel
- Prior art keywords
- calcitonin
- preventing
- manufacture
- treating osteoarthritis
- oral medicament
- Prior art date
Links
- 201000008482 osteoarthritis Diseases 0.000 title abstract 3
- 102000055006 Calcitonin Human genes 0.000 title abstract 2
- 108060001064 Calcitonin Proteins 0.000 title abstract 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 title abstract 2
- 229960004015 calcitonin Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48940003P | 2003-07-23 | 2003-07-23 | |
| PCT/EP2004/008210 WO2005014031A1 (en) | 2003-07-23 | 2004-07-22 | Use of calcitonin in osteoarthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL173002A0 IL173002A0 (en) | 2006-06-11 |
| IL173002A true IL173002A (en) | 2013-09-30 |
Family
ID=34135096
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL173002A IL173002A (en) | 2003-07-23 | 2006-01-05 | Use of calcitonin in the manufacture of oral medication for the prevention or treatment of osteoarthritis |
| IL227988A IL227988A (en) | 2003-07-23 | 2013-08-15 | Pharmaceuticals containing calcitonin for use in the treatment of osteoarthritis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL227988A IL227988A (en) | 2003-07-23 | 2013-08-15 | Pharmaceuticals containing calcitonin for use in the treatment of osteoarthritis |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US7749954B2 (enExample) |
| EP (2) | EP1651249B1 (enExample) |
| JP (2) | JP4716987B2 (enExample) |
| KR (1) | KR101070036B1 (enExample) |
| CN (1) | CN1856321B (enExample) |
| AU (2) | AU2004262906B2 (enExample) |
| BR (1) | BRPI0412265A (enExample) |
| CA (1) | CA2532565C (enExample) |
| ES (2) | ES2436152T3 (enExample) |
| IL (2) | IL173002A (enExample) |
| IS (1) | IS8316A (enExample) |
| MA (1) | MA27929A1 (enExample) |
| MX (1) | MXPA06000807A (enExample) |
| NO (1) | NO330867B1 (enExample) |
| NZ (1) | NZ544645A (enExample) |
| PL (2) | PL2316473T3 (enExample) |
| PT (2) | PT2316473E (enExample) |
| RU (1) | RU2368390C2 (enExample) |
| TN (1) | TNSN06022A1 (enExample) |
| TW (1) | TWI343816B (enExample) |
| WO (1) | WO2005014031A1 (enExample) |
| ZA (1) | ZA200600373B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04005080A (es) * | 2004-05-27 | 2005-11-30 | Aspid S A De C V | Una composicion moduladora de la inflamacion articular cronica a base de colagena-polivinilpirrolidona. |
| WO2007035718A2 (en) | 2005-09-19 | 2007-03-29 | Emisphere Technologies, Inc. | Crystalline forms of the di-sodium salt of n-(5-chlorosalicyloyl)-8-aminocaprylic acid |
| GB0522566D0 (en) * | 2005-11-04 | 2005-12-14 | Novartis Ag | Organic compounds |
| US20080255048A1 (en) | 2005-11-17 | 2008-10-16 | Moise Azria | Pharmaceutical Composition |
| CN103356997A (zh) | 2006-08-31 | 2013-10-23 | 诺瓦提斯公司 | 用于口服递送的包含hgh 的药物组合物 |
| CN107050433A (zh) * | 2007-03-02 | 2017-08-18 | 诺华股份有限公司 | 降钙素的口服施用 |
| WO2009019307A2 (en) * | 2007-08-09 | 2009-02-12 | Novartis Ag | Oral calcitonin compositions and applications thereof |
| KR101344369B1 (ko) | 2007-11-02 | 2013-12-24 | 에미스페어 테크놀로지스, 인코포레이티드 | 비타민 ｂ12 결핍 치료방법 |
| JP5740689B2 (ja) * | 2008-08-18 | 2015-06-24 | エンテラ バイオ エルティーディー． | タンパク質の経口投与用の方法および組成物 |
| RU2537181C2 (ru) * | 2009-03-12 | 2014-12-27 | Нордик Байосайенс А/С | Лечение диабета и метаболического синдрома |
| US9096843B2 (en) | 2009-12-01 | 2015-08-04 | Novo Nordisk A/S | Peptidyl α-hydroxyglycine α-amidating lyases |
| US20120071410A1 (en) | 2010-09-21 | 2012-03-22 | Unigene Laboratories Inc. | Calcitonin products and therapies for treating inflammatory or degenerative diseases |
| SI3095484T1 (en) | 2011-11-02 | 2018-08-31 | Keybioscience Ag | Calcitonin mimetics for the treatment of diseases and disorders |
| KR102019911B1 (ko) | 2011-11-02 | 2019-09-09 | 키바이오사이언스 아게 | 질병 및 장애 치료용 펩타이드 유사체 |
| CN104302761A (zh) * | 2012-03-16 | 2015-01-21 | 生育创新有限公司 | 精细胞的处理 |
| HUE037663T2 (hu) | 2013-11-14 | 2018-09-28 | Keybioscience Ag | Kalcitonin mimetikumok betegségek és rendellenességek kezelésére |
| CN104095828A (zh) * | 2014-07-29 | 2014-10-15 | 中国药科大学 | 一种降钙素口服肠溶组合物及其制备方法 |
| GB201500263D0 (en) | 2015-01-08 | 2015-02-25 | Keybioscience Ag | Calcitonin analogues for treating diseases and disorders |
| US9849125B1 (en) | 2015-11-03 | 2017-12-26 | Banner Lifie Sciences LLC | Anti-overingestion dosage forms |
| GB201704429D0 (en) | 2017-03-21 | 2017-05-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
| GB201707955D0 (en) | 2017-05-18 | 2017-07-05 | Keybioscience Ag | Dual amylin and calcitonin receptor agonists for treating diseases and disorders |
| US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
| KR20190036903A (ko) | 2017-09-28 | 2019-04-05 | (주)휴럼 | 리트세노라이드를 유효성분으로 하는 염증과 골관절염에 대한 예방 및 치료용 약학 조성물 |
| US11274158B2 (en) * | 2018-01-30 | 2022-03-15 | Flagship Pioneering Innovations V, Inc. | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators |
| CN108586601B (zh) * | 2018-05-14 | 2021-07-27 | 四川大学 | 一种骨靶向性鲑鱼降钙素及其制备方法 |
| GB201813677D0 (en) | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
| GB201813678D0 (en) | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Acylated calcitonin mimetics |
| WO2021178454A1 (en) | 2020-03-02 | 2021-09-10 | Magic Leap, Inc. | Immersive audio platform |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US608618A (en) | 1898-08-09 | Thomas millen | ||
| HU203204B (en) | 1987-09-15 | 1991-06-28 | Sandoz Ag | Process for producing suppository containing calcitonin and taurocholic acid |
| JP3501471B2 (ja) * | 1992-06-15 | 2004-03-02 | 旭化成ファーマ株式会社 | カルシトニン類の安定化組成物および安定化法 |
| US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US6191105B1 (en) | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
| US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| TW448172B (en) * | 1996-03-08 | 2001-08-01 | Pharmacia & Upjohn Co Llc | Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| GB9623205D0 (en) * | 1996-11-07 | 1997-01-08 | Eurand Int | Novel pharmaceutical compositions |
| US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| IL145546A0 (en) * | 1999-04-05 | 2002-06-30 | Emisphere Tech Inc | Disodium salts, monohydrates, and ethanol solvates for delivering active agents |
| US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| US6380405B1 (en) | 1999-09-13 | 2002-04-30 | Nobex Corporation | Taxane prodrugs |
| US6436990B1 (en) | 1999-10-27 | 2002-08-20 | Nobex Corporation | 6-methoxy-2-naphthylacetic acid prodrugs |
| US20020012459A1 (en) * | 2000-06-22 | 2002-01-31 | Chips Brain Co. Ltd. | Method and apparatus for detecting stereo disparity in sequential parallel processing mode |
| JP5112595B2 (ja) | 2000-08-29 | 2013-01-09 | バイオコン・リミテッド | 抗炎症活性および抗生物質活性を有する５−ａｓａ誘導体およびこれを用いて疾患を治療する方法 |
| JP2004519428A (ja) | 2000-10-25 | 2004-07-02 | スミスクライン・ビーチャム・コーポレイション | カルシライティック化合物 |
| US7049283B2 (en) * | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| US6479692B1 (en) | 2001-05-02 | 2002-11-12 | Nobex Corporation | Methods of synthesizing acylanilides including bicalutamide and derivatives thereof |
| JP4959917B2 (ja) | 2001-08-17 | 2012-06-27 | ノバルティス アーゲー | 副甲状腺ホルモンフラグメント用経口送達剤としての５−ｃｎａｃ |
-
2004
- 2004-07-22 US US10/565,455 patent/US7749954B2/en not_active Expired - Fee Related
- 2004-07-22 JP JP2006520797A patent/JP4716987B2/ja not_active Expired - Fee Related
- 2004-07-22 BR BRPI0412265-8A patent/BRPI0412265A/pt not_active Application Discontinuation
- 2004-07-22 EP EP04741224A patent/EP1651249B1/en not_active Revoked
- 2004-07-22 MX MXPA06000807A patent/MXPA06000807A/es active IP Right Grant
- 2004-07-22 NZ NZ544645A patent/NZ544645A/xx not_active IP Right Cessation
- 2004-07-22 EP EP10177751.4A patent/EP2316473B1/en not_active Expired - Lifetime
- 2004-07-22 CN CN2004800210875A patent/CN1856321B/zh not_active Expired - Fee Related
- 2004-07-22 CA CA2532565A patent/CA2532565C/en not_active Expired - Fee Related
- 2004-07-22 ES ES10177751T patent/ES2436152T3/es not_active Expired - Lifetime
- 2004-07-22 AU AU2004262906A patent/AU2004262906B2/en not_active Ceased
- 2004-07-22 PL PL10177751T patent/PL2316473T3/pl unknown
- 2004-07-22 PL PL04741224T patent/PL1651249T3/pl unknown
- 2004-07-22 ES ES04741224T patent/ES2398237T3/es not_active Expired - Lifetime
- 2004-07-22 KR KR1020067001391A patent/KR101070036B1/ko not_active Expired - Fee Related
- 2004-07-22 WO PCT/EP2004/008210 patent/WO2005014031A1/en not_active Ceased
- 2004-07-22 RU RU2006105479/14A patent/RU2368390C2/ru not_active IP Right Cessation
- 2004-07-22 PT PT101777514T patent/PT2316473E/pt unknown
- 2004-07-22 PT PT47412242T patent/PT1651249E/pt unknown
- 2004-07-22 TW TW093121910A patent/TWI343816B/zh not_active IP Right Cessation
-
2006
- 2006-01-05 IL IL173002A patent/IL173002A/en not_active IP Right Cessation
- 2006-01-13 ZA ZA200600373A patent/ZA200600373B/en unknown
- 2006-01-20 TN TNP2006000022A patent/TNSN06022A1/en unknown
- 2006-01-23 MA MA28746A patent/MA27929A1/fr unknown
- 2006-02-21 IS IS8316A patent/IS8316A/is unknown
- 2006-02-23 NO NO20060890A patent/NO330867B1/no not_active IP Right Cessation
-
2008
- 2008-06-30 AU AU2008202879A patent/AU2008202879B2/en not_active Ceased
-
2010
- 2010-06-21 US US12/819,583 patent/US8765675B2/en not_active Expired - Fee Related
-
2011
- 2011-02-22 JP JP2011035273A patent/JP2011121987A/ja active Pending
-
2013
- 2013-08-15 IL IL227988A patent/IL227988A/en not_active IP Right Cessation
-
2014
- 2014-06-02 US US14/293,459 patent/US20140271735A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL173002A (en) | Use of calcitonin in the manufacture of oral medication for the prevention or treatment of osteoarthritis | |
| PL1656346T3 (pl) | 1,2,3,4-Tetrapodstawiony indol do leczenia chorób dróg oddechowych | |
| TW200738270A (en) | Method of treating depression using a TNFα antibody | |
| AP2005003350A0 (en) | 3-(3,5-dioxo-4,5-dihydro-3H-(1,2,4) triazin-2-yl)-benzamide derivatives as p2X7 -inhibitors for the treatment of inflammatory diseases. | |
| IL220043B (en) | Methods of producing alpha-galactosidase a preparations and their uses | |
| PT2050447T (pt) | Forma de dosagem oral contendo entacapona | |
| MX2010002498A (es) | Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol. | |
| SI1855677T1 (sl) | 3,11 b-cis-dihidrotetrabenazin za zdravljenje shizofrenije in drugih psihoz | |
| ZA200604114B (en) | Use of substituted 2-aminotetralines for the preventative treatment of parkinson's disease | |
| IL164896A0 (en) | Immunoconjugates for the treatment of tumours | |
| AU2003258145A8 (en) | Substituted phenylindoles for the treatment of hiv | |
| MXPA02010952A (es) | Composicion reductora para el tratamiento de las fibras queratinicas que comprende silicona aminada particular. | |
| WO2003084476A3 (en) | Treatment of lung disorder | |
| IL162818A0 (en) | Combination therapy for the treatment of bacterialinfections | |
| WO2004110373A3 (en) | Therapeutic vaccine compositions for the treatment of type 1 diabetes | |
| MXPA05012742A (es) | Composiciones de tratamiento para el cabello. | |
| HRP20041160A2 (en) | Novel combination for the treatment of airway disorders | |
| DK1523985T3 (da) | Ikke-radioaktivt strontiumholdigt middel til behandling af kræft | |
| MXPA05009428A (es) | Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas. | |
| TW200508196A (en) | Hydroxamic acids useful in the treatment of hyper-proliferative disorders | |
| GB0221157D0 (en) | Novel treatment | |
| GB0209135D0 (en) | Fiber treatment composition | |
| GB0201025D0 (en) | The treatment of degenerative diseases | |
| AU2003260723A1 (en) | Use of vinca alkaloyds, taxane, cryptophycine, ephitoline or eleutherobine for treating alzheimer | |
| GB0212790D0 (en) | Medicament for the treatment of diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |